The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1

The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1

Abstract Background Therapeutic antibodies targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis induce potent and durable anti-tumor responses in multiple types of cancers. However, only a subset of patients benefits from anti-PD-1/PD-L1 therapies. As a negative re...

Full description

Bibliographic Details
Main Authors: Ming Yi, Jing Zhang, Anping Li, Mengke Niu, Yongxiang Yan, Ying Jiao, Suxia Luo, Pengfei Zhou, Kongming Wu
Format: Article
Language:English
Published: BMC 2021-02-01
Series:Journal of Hematology & Oncology
Subjects:
Cancer immunotherapy
PD-1
PD-L1
TGF-β
The tumor microenvironment
Bispecific antibody
Online Access:https://doi.org/10.1186/s13045-021-01045-x

Internet

https://doi.org/10.1186/s13045-021-01045-x

Similar Items